• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Shire PLC ADR

Shire PLC ADR

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. UPDATE: Dyax shares jump 55% on 'best-in-class' potential for new drug

    UPDATE: Dyax shares jump 55% on 'best-in-class' potential for new drug

  2. Dyax shares jump 40% on 'best-in-class' potential for new drug

    Dyax shares jump 40% on 'best-in-class' potential for new drug

  3. Lessons of the Winter Selloff

    New River Pharmaceuticals NRPH announced a buyout offer Tuesday from Shire SHPGY for $64 per share in cash, just over 3 times our fair value estimate. We'll raise our New River fair value estimate to reflect the offer price, since the transaction is already approved by both boards as well as New ...

  4. ETFs and Mutual Funds: Why not both?

    Shire Pharmaceuticals SHPGY recently announced that the FDA approved its Hunter syndrome therapy, Elaprase, for marketing. We're slightly raising our fair value estimate to account for this new addition to Shire's product portfolio. Shire received rights to Elaprase, a human enzyme replacement ...

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.